Everything below concerns 鼻内给药. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
| Property | Value | Notes |
|---|---|---|
| 结构类别 | 线性合成七肽 | 无环化结构，不含二硫键 |
| 氨基酸序列 | Met-Glu-His-Phe-Pro-Gly-Pro | N 端为甲硫氨酸 |
| 分子量 | 约 814 Da | 游离碱形式的计算值 |
| 外观 | 白色至类白色粉末 | 具吸湿性 |
| 溶解性 | 易溶于水 | 亦可溶于甲醇等极性溶剂 |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
Hydrogen cyanide is a bulk chemical; global production in 2001 was approximately 2.6 million tons. Key derivatives produced from it include adiponitrile, acetone cyanohydrin, sodium cyanide, and cyanuric chloride. Chelating agents are also synthesized from hydrogen cyanide, for example ethylenediaminetetraacetic acid from formaldehyde, ethylenediamine, hydrogen cyanide, and sodium hydroxide. An important industrial route to amino acids is the Strecker synthesis, in which hydrogen cyanide serves as a starting material. A quantitatively important amino acid is methionine, which is produced from acrolein, hydrogen cyanide, and hydrogen sulphide and is used primarily in animal feed.
The cellular reproduction process of meiosis was discovered by Oscar Hertwig in 1876. Mitosis was discovered several years later in 1882 by Walther Flemming. Hertwig studied sea urchins, and noticed that each egg contained one nucleus prior to fertilization and two nuclei after. This discovery proved that one spermatozoon could fertilize an egg, and therefore proved the process of meiosis. Hermann Fol continued Hertwig's research by testing the effects of injecting several spermatozoa into an egg, and found that the process did not work with more than one spermatozoon. Flemming began his research of cell division starting in 1868. The study of cells was an increasingly popular topic in this time period. By 1873, Schneider had already begun to describe the steps of cell division. Flemming furthered this description in 1874 and 1875 as he explained the steps in more detail. He also argued with Schneider's findings that the nucleus separated into rod-like structures by suggesting that the nucleus actually separated into threads that in turn separated. Flemming concluded that cells replicate through cell division, to be more specific mitosis. Matthew Meselson and Franklin Stahl are credited with the discovery of DNA replication. Watson and Crick acknowledged that the structure of DNA did indicate that there is some form of replicating process. However, there was not a lot of research done on this aspect of DNA until after Watson and Crick. People considered all possible methods of determining the replication process of DNA, but none were successful until Meselson and Stahl.
Cyclodextrins were called "cellulosine" when first described by A. Villiers in 1891. Soon after, F. Schardinger identified the three naturally occurring cyclodextrins: α, β, and γ, referred to as "Schardinger sugars". For 25 years, between 1911 and 1935, Hans Pringsheim in Germany was the leading researcher in this area, demonstrating that cyclodextrins formed stable aqueous complexes with many other chemicals. By the mid-1970s, each of the natural cyclodextrins had been structurally and chemically characterized and many more complexes had been studied. Since the 1970s, extensive work has been conducted by Szejtli and others exploring encapsulation by cyclodextrins and their derivatives for industrial and pharmacologic applications. Among the processes used for complexation, the kneading process seems to be one of the best.
Sources: en.wikipedia.org
=== Promotion and release === Microsoft has been a major supporter for Compulsion Games in backing We Happy Few, leading to the game having its console debut on the Xbox One. Microsoft announced We Happy Few as part of their press conferences at Gamescom in August 2015, Electronic Entertainment Expo 2016. and Electronic Entertainment Expo 2018. This last presentation was accompanied by the news that Microsoft Studios had acquired Compulsion Games as part of their in-house studios. In August 2017, Compulsion Games announced that they have partnered with Gearbox Software for financial support to expand the game into a retail-length title, planned to release on 13 April 2018. Compulsion's Provost had known Gearbox's Randy Pitchford prior to their release of Contrast, and Contrast's visual style had caught Pitchford's attention, but the studio lacked a publishing arm at the time. By E3 2016, where Microsoft presented We Happy Few as part of its press event, Gearbox operated its Gearbox Publishing division led by Steve Gibson. Gibson, also interested in what We Happy Few offered, invited Compulsion to their offices to discuss financing and publishing opportunities for the game. Gearbox's funding helped Compulsion expand their team four-fold and expand the scope and narrative of the game. With Gearbox's help, Compulsion was able to develop We Happy Few for the PlayStation 4, while Gearbox will publish retail versions for all platforms; Microsoft's acquisition of the studio did not impact this publishing deal.
Bukele's relationship with the FMLN began to deteriorate after he became mayor of San Salvador. He clashed with other party members on Twitter, and frequently resisted FMLN party leadership. Bukele became a strong critic of Salvador Sánchez Cerén, the FMLN president of El Salvador who was elected in 2014. He threatened to leave the party in 2015 if the FMLN-led government reappointed Luis Martínez as the country's attorney general, describing Martínez as "a gangster, very corrupt, [and] the worst of the worst". The FMLN relented and replaced Martínez, and Bukele later admitted that his threat to leave the party "was a bluff". In September 2017, San Salvador FMLN member Xóchitl Marchelli alleged that Bukele had thrown an apple at her, calling her a "damn traitor" ("maldita traidora") and a "witch" ("bruja"). Bukele did not attend an FMLN ethics tribunal on 7 October 2017, saying that the tribunal was biased in favor of Marchelli. On 10 October 2017, he was expelled from the party after the tribunal determined that he had engaged in "defamatory acts" ("actos difamatorios") against the party, showed "disrespect" ("irrespeto") for women's rights and the party's statutes, and made "disqualifying comments" ("comentarios descalificadores") to party members. Marchelli sued Bukele through the Specialized Investigative Court, but sent a letter to the court in October 2018 saying that she would no longer pursue the matter for health reasons. Despite Marchelli's withdrawal, the FGR proceeded with the case. On 29 March 2019, the Specialized Sentencing Court acquitted Bukele.
Half-Life 2: Episode One is a 2006 first-person shooter game developed and published by Valve for Windows. It continues the story of Half-Life 2 (2004). As the scientist Gordon Freeman, players must escape City 17 with Gordon's companion Alyx Vance. Like previous Half-Life games, Episode One combines shooting, puzzles and storytelling. After the six-year development of Half-Life 2, Valve switched to episodic development, planning to release games more frequently. They focused on developing the character of Alyx and expanded her artificial intelligence. Episode One uses an updated version of Valve's Source engine, with new lighting and animation technology. Episode One received mostly positive reviews; the co-operative gameplay with Alyx received particular praise, although the short length was criticized. It was ported to Xbox 360 and PlayStation 3 as part of the 2007 compilation The Orange Box. Episode Two followed in 2007.
Sources: en.wikipedia.org
The conflict is commonly referred to simply as "the Boer War" because the First Boer War (1880–81) was much smaller. Boer (meaning "farmer") is the common name for Afrikaans-speaking white South Africans descended from the Dutch East India Company's settlers at the Cape of Good Hope. Among some South Africans, it is known as the (Second) Anglo–Boer War. In Afrikaans, it is called the 'Tweede Vryheidsoorlog ("Second Freedom War"), 'Tweede Boereoorlog ("Second Boer War"), Anglo–Boereoorlog ("Anglo–Boer War") or Engelse oorlog ("English War"). In South Africa, it is officially called the South African War. According to a 2011 BBC report, "most scholars prefer to call the war of 1899–1902 the South African War, thereby acknowledging that all South Africans, white and black, were affected by the war and that many were participants".
=== Eyes === Cases of severe conjunctivitis were reported after technicians looked into powered waveguides. Microwave-induced cataracts have been reported. Experiments on rabbits and dogs, mostly in the UHF range of frequencies, shown that the ocular effects are confined to eyelids and conjunctiva (as e.g. anterior segment keratitis or iritis). Cataracts were observed at several workers exposed to radiofrequency radiation, but in some of the cases the cause was unrelated to the RF exposure and in the other cases the evidence was incomplete or inconclusive. Some sources however mention incidence of microwave-related injuries of ocular lens and retina and the possibility of thermal effects to cause cataracts or focal tissue burns (including keratitis). For the near field 2.45 GHz frequency, the minimum power density to cause cataracts in rabbits was found to be 150 mW/cm2 for 100 minutes; a retrolental temperature of 41 °C was necessary to be achieved. When the eye temperature was kept low by external cooling, cataracts were not produced by higher field intensities; that supports the hypothesis of a thermal mechanism being involved.
== See also == Ancient DNA Biocultural anthropology Biological distance analysis Odontometrics Osteoarchaeology Paleopathology Zooarchaeology 2025 in bioarchaeology 2026 in bioarchaeology Dental analysis in archaeology
Sources: en.wikipedia.org
不存在。它是依据 ACTH 的一段序列人工设计的分子，天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号，而非天然物质名。
Semax 对应 ACTH 第 4 至第 10 位的片段，并在两端做了替换与延长，使其不再具备促肾上腺皮质激素的典型内分泌活性。这一改动同时改变了它在体内的稳定性与分布特征。
俄罗斯将其列为处方药物，需要医生开具处方。多数其他国家把它当作研究化合物，不能作为药品销售或宣称疗效。具体合法性取决于当地法规。
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.